Desire starts in the brain.
PT-141 (bremelanotide) is a melanocortin receptor agonist. Melanocortin receptors are found in the central nervous system and are involved in regulating sexual arousal, appetite, and other autonomic functions. PT-141 activates the MC3R and MC4R receptors specifically — the ones most associated with sexual desire and arousal in the literature.
The result is an increase in sexual desire that originates centrally — through the nervous system — rather than peripherally through vascular effects. This is why PT-141 works for a type of problem that PDE5 inhibitors (Viagra, Cialis) don't address: patients whose issue is not mechanical function or blood flow, but rather diminished desire and arousal.
PT-141 received FDA approval in 2019 under the brand name Vyleesi for premenopausal women with hypoactive sexual desire disorder. It's also widely used off-label in men with similar presentations.
For desire that's gone quiet.
PT-141 is most appropriate for patients — both men and women — who experience low libido, diminished sexual interest, or difficulty achieving arousal that isn't primarily mechanical in nature. If the plumbing works but the drive isn't there, this is the peptide designed for that problem.
It's also sometimes used alongside PDE5 inhibitors for patients who need both the central desire effect and the peripheral vascular effect.
- Low libido and sexual desire
- Hypoactive sexual desire disorder (HSDD)
- Arousal difficulties in both sexes
- Sexual dysfunction with a central (brain) component
- Complement to PDE5 inhibitors when both effects are needed
As needed. Simple and effective.
PT-141 is taken as needed, approximately 45 minutes to 2 hours before sexual activity. It's a subcutaneous injection — typically at the abdomen. The effect typically lasts 12–24 hours.
Because it's an as-needed medication rather than a daily protocol, dosing frequency is self-directed within prescribed parameters. We start at a lower dose to assess tolerance before adjusting.
| Aspect | Details |
|---|---|
| Onset | 45 minutes – 2 hours |
| Duration | 12–24 hours |
| Starting dose | 0.75mg subcutaneous |
| Typical dose range | 0.75–2mg per use |
| Frequency | As needed, not more than once per 24 hours |
What you should know
Flushing — a warm sensation, often in the face and neck — is the most common side effect and occurs in many patients. It's generally mild and transient, resolving within 1–2 hours.
Nausea is the second most common complaint, again usually mild and transient. Some patients experience a mild headache.
PT-141 can cause a transient increase in blood pressure. This is relevant for patients with cardiovascular conditions, and we screen for this as part of the initial evaluation.
Common questions about PT-141
Completely different mechanism. Viagra (and Cialis, Levitra) work by increasing blood flow to the genitals — a peripheral, vascular effect. PT-141 activates desire pathways in the brain. They treat different problems. Some patients benefit from both; others need only one. The consultation helps determine which applies to you.
Yes — and it's FDA approved for women with hypoactive sexual desire disorder. The melanocortin pathway it targets is relevant in both sexes. Clinical experience in women is positive.
Most patients describe a genuine increase in desire and arousal — a feeling of interest that had been absent. Some also report increased emotional warmth. The experience is generally described as natural-feeling rather than artificial.
No. Low libido can occur at any age for various reasons — stress, hormonal shifts, medications, relationship factors, or simply biological variation. PT-141 is appropriate for adults of any age where the presentation fits.
We review your labs, goals, and health history before recommending any protocol. Available in-person in St. Louis or via secure telehealth.
📅 Request a Consultation →